Εμφανίζονται 1 - 20 Αποτελέσματα από 55 για την αναζήτηση '"периферическая нейропатия"', χρόνος αναζήτησης: 0,93δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
    Academic Journal

    Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; № 5.83 (2016); 55-60
    МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 5.83 (2016); 55-60
    МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 5.83 (2016); 55-60

    Περιγραφή αρχείου: application/pdf

  3. 3
    Academic Journal

    Συνεισφορές: Dr. A. Soufla would like to express her gratitude to Pr. Dr. Panagiotis Kokotis for his valuable support and assistance during the research process., Доктор A. Soufla выражает благодарность проф. P. Kokotis за его ценную поддержку и помощь в ходе исследования.

    Πηγή: Neuromuscular Diseases; Том 14, № 2 (2024); 38‑43 ; Нервно-мышечные болезни; Том 14, № 2 (2024); 38‑43 ; 2413-0443 ; 2222-8721

    Περιγραφή αρχείου: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/601/383; Mendell L.M. Computational functions of neurons and circuits signaling injury: Relationship to pain behavior. Proc Natl Acad Sci USA 2011;108(Suppl 3):15596–601. DOI:10.1073/pnas.1012195108; Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009;89(2):707–58. DOI:10.1152/physrev.00025.2008; Woolf C.J. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011;152(3 Suppl):S2–15. DOI:10.1016/j.pain.2010.09.030; Zhou L., Pioro E.P. Familial ALS with SOD1 mutation misdiagnosed with polyradiculopathy and myopathy. Amyotroph Lateral Scler 2009;10(5–6):476–8. DOI:10.3109/17482960802449278; Woolf C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140:441–51. DOI:10.7326/0003-4819-140-8-200404200-00010; Horowitz S.H. The diagnostic workup of patients with neuropathic pain. Med Clin North Am 2007;91(1):21–30. DOI:10.1016/j.mcna.2006.10.002; Borchers A.T., Gershwin M.E. Complex regional pain syndrome: A comprehensive and critical review. Autoimmun Rev 2014;13(3):242–65. DOI:10.1016/j.autrev.2013.10.006; Devigili G., Tugnoli V., Penza P. et al. The diagnostic criteria for small fibre neuropathy: From symptoms to neuropathology. Brain 2008;131(Pt 7):1912–25. DOI:10.1093/brain/awn093; Kehlet H., Jensen T.S., Woolf C.J. Persistent postsurgical pain: Risk factors and prevention. Lancet 2006;367(9522):1618–25. DOI:10.1016/S0140-6736(06)68700-X; Gold S.M., Stucky L.C. The senses: A comprehensive reference. 2nd edn. 2020.; Belmonte C., Viana F. Nociceptor responses. Encyclopedia of Neuroscience, 2009.; Jonas R., Namer B., Stockinger L. et al. Tuning in C-nociceptors to reveal mechanisms in chronic neuropathic pain. Ann Neurol 2018;83(5):945–57. DOI:10.1002/ana.25231; Truini A., Biasiotta A., Di Stefano G. et al. Does the epidermal nerve fibre density measured by skin biopsy in patients with peripheral neuropathies correlate with neuropathic pain? Pain 2014;155(4):828–32. DOI:10.1016/j.pain.2014.01.022; Tesfaye S., Boulton A.J., Dyck P.J. et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285–93. DOI:10.2337/dc10-1303; Lauria G., Hsieh S.T., Johansson O. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010;17(7):903–12, e44–9. DOI:10.1111/j.1468-1331.2010.03023.x; Nolano M., Provitera V., Caporaso G. et al. Cutaneous innervation of the human face as assessed by skin biopsy. J Anat 2013;222(2):161–9. DOI:10.1111/joa.12001; Haefeli M., Elfering A. Pain assessment. Eur Spine J 2006;15(Suppl 1): S17–24. DOI:10.1007/s00586-005-1044-x; Closs S.J., Barr B., Briggs M. et al. A comparison of five pain assessment scales for nursing home residents with varying degrees of cognitive impairment. J Pain Symptom Manage 2004;27(3):196–205. DOI:10.1016/j.jpainsymman.2003.12.010; Jensen M.P., Karoly P., Braver S. The measurement of clinical pain intensity: A comparison of six methods. Pain 1986;27(1):117–26. DOI:10.1016/0304-3959(86)90228-9; Sauerstein K., Liebelt J., Namer B. et al. Low-frequency stimulation of silent nociceptors induces secondary mechanical hyperalgesia in human skin. Neuroscience 2018;387:4–12. DOI:10.1016/j.neuroscience.2018.03.006; https://nmb.abvpress.ru/jour/article/view/601

  4. 4
    Academic Journal

    Πηγή: Malignant tumours; Том 14, № 1 (2024); 74-82 ; Злокачественные опухоли; Том 14, № 1 (2024); 74-82 ; 2587-6813 ; 2224-5057

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/1288/918; William J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594–608. https://doi.org/10.6004/jnccn.2023.0031; Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020; NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category =1&id =1462; NCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf; NCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf; Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020; Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772–781. https://doi.org/10.1002/ana.24951; Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33(1):15–49. https://doi.org/10.1053/j.seminoncol.2005.12.010; Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16(5):708–16. https://doi.org/10.1634/theoncologist.2010-0248; Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312; Kalfakis N., Panas M., Karadima G., et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002;59(9):1470–1. https://doi.org/10.1212/01.wnl.0000032505.45389.94; Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337–40. https://doi.org/10.1212/01.wnl.0000043691.53710.53; Chauvenet A.R., Shashi V., Selsky C., et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25(4):316–20. https://doi.org/10.1097/00043426-200304000-00010; Gu J., Lu H., Chen C., et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021;29(12):7461–7469. https://doi.org/10.1007/s00520-021-06321-7; McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013$19(20):5769–5776. https://doi.org/10.1158/1078-0432.CCR-13-0774; Jennaro T.S., Fang F., Kidwell K.M., et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 2020;180(3):707–714. https://doi.org/10.1007/s10549-020-05584-8; Hershman D.L., Till C., Wright J.D., et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34(25):3014–22. https://doi.org/10.1200/JCO.2015.66.2346; Solomon L.R. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer 2016;24(8):3489–94. https://doi.org/10.1007/s00520-016-3175-5; EL-Najjar S.E., Naser I.A., AL-Wahidi K.M. Is Functional Vitamin B12 Deficiency a Risk Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients? Research Square 2022. https://doi.org/10.21203/rs.3.rs-1667065/v2; Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174; Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633–42. https://doi.org/10.1200/JCO.2005.04.0543; de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47. https://doi.org/10.1200/JCO.2000.18.16.2938; Park S.B., Goldstein D., Krishnan A.V., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419–37. https://doi.org/10.3322/caac.21204. PMID: 2459086; Loprinzi C.L., Lacchetti C., Bleeker J., et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–3348. https://doi.org/10.1200/JCO.20.01399; Jordan B., Margulies A., Cardoso F., et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003; Avallone A., Bimonte S., Cardone C., et al. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res 2022;42(10):4667–4678. https://doi.org/10.21873/anticanres.15971; Akin E.J., Alsaloum M., Higerd G.P., et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021;144(6):1727–1737. https://doi.org/10.1093/brain/awab113; Krukowski K., Ma J., Golonzhka O., et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 2017;158(6):1126–1137. https://doi.org/10.1097/j.pain.0000000000000893; Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. https://doi.org/10.1016/j.expneurol.2011.08.016; Fumagalli G., Monza L., Cavaletti G., et al. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2021:11:626687. https://doi.org/10.3389/fimmu.2020.626687; Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813; Farshchian N., Alavi A., Heydarheydari S., et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018;82:787–793. https://doi.org/10.1007/s00280-018-3664-y; Matsuoka H., Clark K., Fazekas B., et al. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open 2022;12(2):e050182. https://doi.org/10.1136/bmjopen-2021-050182; Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31(20):2627–33. https://doi.org/10.1200/JCO.2012.44.8738; Kautio A.L., Haanpää M., Saarto T., Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31–9. https://doi.org/10.1016/j.jpainsymman.2007.02.043; Gedlicka C., Scheithauer W., Schüll B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359–61. https://doi.org/10.1200/JCO.2002.99.502; Guo Y., Jones D., Palmer J.L., et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22(5):1223–31. https://doi.org/10.1007/s00520-013-2075-1; Dinicola S., Fuso A., Cucina A., et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci 2018;22(14):4739–4754. https://doi.org/10.26355/eurrev_201807_15534.2018; Mitchell P.L., Goldstein D., Michael M., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6(2):146–51. https://doi.org/10.3816/CCC.2006.n.032; https://www.malignanttumors.org/jour/article/view/1288

  5. 5
  6. 6
    Academic Journal

    Συγγραφείς: Singh, К., Yuzvenko, Т.

    Πηγή: Clinical Endocrinology and Endocrine Surgery. Клінічна ендокринологія та ендокринна хірургія; № 1 (2020); 43-48
    Clinical Endocrinology and Endocrine Surgery; № 1 (2020); 43-48
    Clinical Endocrinology and Endocrine Surgery. Клиническая эндокринология и эндокринная хирургия; № 1 (2020); 43-48

    Περιγραφή αρχείου: application/pdf

  7. 7
  8. 8
  9. 9
    Academic Journal

    Πηγή: Медицина болю, Vol 4, Iss 2, Pp 41-52 (2019)
    Medicina bolu; Том 4 № 2 (2019): Pain medicine; 41-52
    Pain medicine; Vol 4 No 2 (2019): Pain medicine; 41-52

    Περιγραφή αρχείου: application/pdf; text

  10. 10
    Academic Journal
  11. 11
    Academic Journal

    Συγγραφείς: Perepada, Ganna

    Πηγή: ScienceRise: Medical Science; № 1 (28) (2019); 24-31
    ScienceRise. Medical Science; № 1 (28) (2019); 24-31

    Περιγραφή αρχείου: application/pdf

  12. 12
  13. 13
  14. 14
    Academic Journal
  15. 15
    Academic Journal

    Πηγή: Neuromuscular Diseases; Том 10, № 4 (2020); 12-26 ; Нервно-мышечные болезни; Том 10, № 4 (2020); 12-26 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2020-10-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/404/279; Barreto L.C.L.S., Oliveira F.S., Nunes P.S. et al. Epidemiologic study of Charcot–Marie–Tooth disease: a systematic review. Neuroepidemiology 2016;46(3):157–65. DOI:10.1159/000443706. PMID: 26849231.; Baets J., Timmerman V. Inherited peripheral neuropathies: a myriad of genes and complex phenotypes. Brain 2011;134(6):1587–90. DOI:10.1093/brain/awr114.; Drew A.P., Zhu D., Kidambi A. et al. Improved inherited peripheral neuropathy genetic diagnosis by whole-exome sequencing. Mol Genet Genomic Med 2015;3(2):143–54. DOI:10.1002/mgg3.126. PMID: 25802885.; Hartley T., Wagner J.D., WarmanChardon J. et al. Whole-exome sequencing is a valuable diagnostic tool for inherited peripheral neuropathies: Outcomes from a cohort of 50 families. Clin Genet 2018;93(2):301–9. DOI:10.1111/cge.13101. PMID: 28708278.; Schabhüttl M., Wieland T., Senderek J. et al. Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges. J Neurol 2014;(261):970–82. DOI:10.1007/s00415-014-7289-8. PMID: 24627108.; Gonzaga-Jauregui C., Harel T., Gambin T. et al. Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy. Cell Rep 2015;12(7):1169–83. DOI:10.1016/j.celrep.2015.07.023. PMID: 26257172.; Richards S., Aziz N., Bale S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;(17):405–23. DOI:10.1038/gim.2015.30. PMID: 25741868.; Щагина О.А., Дадали Е.Л., Федотов В.П., Поляков А.В. Спектр мутаций в гене MFN2 у больных наследственной моторно-сенсорной нейропатией II А типа. Медицинская генетика 2006;5(9):21–6.; Дадали Е.Л., Щагина О.А., Федотов В.П. Клинико-генетические особенности моторно-сенсорной нейропатии IIА типа. Анналы клинической и экспериментальной неврологии 2007;1(4):10–5.; Миловидова Т.Б., Дадали Е.Л., Федотов В.П. и др. Клинико-генетичекие корреляции при наследственной моторно-сенсорной нейропатии, вызванной мутациями в гене МРZ (P0). Журнал неврологии и психиатрии им. С.С. Корсакова 2011;111(12):48–55.; Latour P., Thauvin-Robinet C., BaudeletMéry C. et al. A major determinant for binding and aminoacylation of tRNAAla in cytoplasmic alanyl-trna synthetase is mutated in dominant axonal charcotmarie-tooth disease. Am J Hum Genet 2010;86(1):77–82. DOI:10.1016/j.ajhg.2009.12.005. PMID: 20045102.; Shchagina O.A., Milovidova T.B., Murtazina A.F. et al. HINT1 gene pathogenic variants: the most common cause of recessive hereditary motor and sensory neuropathies in Russian patients. Mol Biol Rep 2020;(47):1331–7. DOI:10.1007/s11033-019-05238-z.; Дадали Е.Л., Никитин С.С., Курбатов С.А. и др. Клинико-генетические характеристики аутосомно-рецессивной аксональной нейропатии с нейромиотонией у больных из России. Нервно-мышечные болезни 2017;7(3): 47–55. DOI:10.17650/2222-8721-2017-7-3-47-55.; https://nmb.abvpress.ru/jour/article/view/404

  16. 16
  17. 17
    Academic Journal

    Πηγή: Pain medicine; Vol. 4 No. 2 (2019): Pain medicine; 41-52 ; Medicina bolu; Том 4 № 2 (2019): Pain medicine; 41-52 ; 2519-2752 ; 2414-3812

    Περιγραφή αρχείου: application/pdf

  18. 18
  19. 19
  20. 20